Unexpected Neurotoxicity of Etoposide Phosphate Administered in Combination with Other Chemotherapeutic Agents after Blood-Brain Barrier Modification to Enhance Delivery, Using Propofol for General Anesthesia, in a Rat Model
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 47 (1), 199-207
- https://doi.org/10.1097/00006123-200007000-00041
Abstract
Osmotic blood-brain barrier disruption (BBBD) increases brain and brain tumor delivery of chemotherapeutic agents, which results in increased efficacy against brain tumors. We previously noted that the use of propofol anesthesia for BBBD increased the percentage of successful disruptions, resulting in delivery of increased amounts of chemotherapeutic drugs. This study evaluated the neurotoxicity of combination chemotherapeutic administration with this enhanced delivery system. Osmotic BBBD was performed in Long-Evans rats with isoflurane (n = 11) or propofol (n = 90) anesthesia. Carboplatin and/or melphalan, methotrexate, or etoposide phosphate was administered intra-arterially (IA) after BBBD using propofol anesthesia. Animals were assessed for systemic and neurological toxicity. Animals were killed for neuropathological evaluation 30 days after treatment. With propofol or isoflurane anesthesia, BBBD alone produced no systemic or neurological toxicity. Single agents were relatively non-neurotoxic when administered IA with BBBD, as were the combinations of carboplatin or melphalan with methotrexate. Etoposide phosphate in combination with any other agent was observed to be highly neurotoxic if both agents were administered after BBBD. Administration of etoposide phosphate before BBBD completely eliminated neurotoxicity, although acute pulmonary toxicity occurred with any combination of etoposide phosphate and methotrexate, regardless of the timing of administration. Neurotoxicity was significantly increased for etoposide phosphate combination groups, particularly when both drugs were administered IA after BBBD. This increase in neurotoxicity may reflect on increase in drug delivery observed with propofol anesthesia. The neurotoxicity of IA administered etoposide phosphate with BBBD and propofol anesthesia could be minimized by administering etoposide phosphate IA before BBBD and administering carboplatin or melphalan IA after BBBD.Keywords
This publication has 11 references indexed in Scilit:
- Enhanced Delivery Improves the Efficacy of a Tumor-specific Doxorubicin Immunoconjugate in a Human Brain Tumor Xenograft ModelNeurosurgery, 2000
- Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumorsCancer, 2000
- The Influence of Anesthetic Choice, PaCO2, and Other Factors on Osmotic Blood-Brain Barrier Disruption in Rats with Brain Tumor XenograftsAnesthesia & Analgesia, 1999
- Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flowJournal of Neuro-Oncology, 1997
- Toxicity and Efficacy of Carboplatin and Etoposide in Conjunction with Disruption of the Blood-Brain Tumor Barrier in the Treatment of Intracranial NeoplasmsNeurosurgery, 1995
- Selective intra-arterial chemotherapy with a combination of etoposide and cisplatin for malignant gliomas: Preliminary reportSurgical Neurology, 1994
- Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumorsCancer, 1991
- Intravascular streaming during carotid artery infusionsJournal of Neurosurgery, 1991
- Blood-Brain Barrier Disruption in the Treatment of Brain TumorsPublished by Springer Nature ,1989
- Etoposide-induced blood-brain barrier disruptionJournal of Neurosurgery, 1984